Is Genedata or Remesh better?

Neither clearly leads. Genedata starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.

Which is cheaper, Genedata or Remesh?

Genedata starts at On request and Remesh at On request.

Does Genedata or Remesh run on more platforms?

Genedata runs on Web, On-premise, Private cloud. Remesh runs on Web, API.

What is Genedata best used for?

Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Remesh is typically brought in for.

What can Genedata do that Remesh cannot?

Genedata covers Screener, Biologics, Bioprocess, Expressionist. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.

Research · head to head

Genedata vs Remesh

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From: On request
Rated: -

Full review Website

Remesh

Research

Live AI-moderated conversations with hundreds of participants at once, analysed in real time

From: On request
Rated: -

Full review Website

The short version

Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Remesh pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
They diverge on capability: Genedata covers Screener, Remesh covers Live moderated sessions.
Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and Remesh actually diverge.

Attributes where Genedata and Remesh differ
Attribute	Genedata	Remesh
Platforms	Web, On-premise, Private cloud	Web, API

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

Screener
Biologics
Bioprocess
Expressionist
Selector
Profiler
Instrument integration
GxP-capable deployments

Only in Remesh

Live moderated sessions
Collective dialogue
Flex asynchronous studies
Video research
Remy AI assistant
On-Demand Recruit
Real-time theme analysis
Practice sessions

What people use each for

The jobs each tool is most often brought in to do.

Genedata

A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Remesh
A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Remesh
A process development group standardising bioprocess run data across sites for modelling and scale-upnot Remesh
A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Remesh

Remesh

A brand team that needs to test three positioning statements with 400 target customers and know by the end of the day which one lands and with whomnot Genedata
An HR function running an employee listening session across several thousand staff where anonymity and volume both matternot Genedata
A public affairs team needing rapid citizen consultation on a policy option with evidence of how widely each objection is heldnot Genedata
An insights team that has to replace six focus groups with one session because fieldwork time has been cut and the decision cannot waitnot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

Remesh

Pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
The public review picture is inconsistent in a way worth investigating: a small number of positive buyer reviews on G2 sit alongside a poor Trustpilot rating driven mostly by participant complaints, so ask directly how participants are recruited and compensated before running a study on your own customers.
Funding has slowed sharply, from a 25 million USD round in 2021 to a 4.25 million USD round in late 2022, so procurement teams at large organisations should expect to run a vendor viability review.
The collective dialogue mechanic rewards views that many participants recognise and vote for, which systematically under-weights genuinely novel minority insight, so it is a poor fit for exploratory discovery work where the outlier is the point.
The discussion guide builder, especially spreadsheet import, is reported as unreliable, and because sessions are live with recruited participants a tooling failure during setup is expensive rather than merely annoying.

Pricing, plan by plan

Genedata

On request

Genedata platform licence$undefined/year
- Each platform, such as Screener or Biologics, licensed separately
- Annual enterprise subscription scoped on users, sites and data volume
- Implementation and scientific configuration services quoted as a separate programme

Remesh

On request

Remesh$undefined/year
- Live moderated sessions
- Flex asynchronous studies
- Video research

Which should you pick?

Choose Genedata if

You need screener.
You work on Web, On-premise, Private cloud.
You also want biologics.

Genedata review

Choose Remesh if

You need live moderated sessions.
You work on Web, API.
You also want collective dialogue.

Remesh review

Questions people ask

Is Genedata or Remesh better?: Neither clearly leads. Genedata starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or Remesh?: Genedata starts at On request and Remesh at On request.
Does Genedata or Remesh run on more platforms?: Genedata runs on Web, On-premise, Private cloud. Remesh runs on Web, API.
What is Genedata best used for?: Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Remesh is typically brought in for.
What can Genedata do that Remesh cannot?: Genedata covers Screener, Biologics, Bioprocess, Expressionist. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

Remesh: How many people can join one session?

Sessions are designed for several hundred participants at once, which is the core reason to choose it over a conventional focus group.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

Remesh: Does it publish pricing?

No. Contracts are quoted annually, typically scoped by session volume, and third-party estimates place them in the tens of thousands of dollars per year.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

Remesh: Can it replace a survey?

Not entirely. It produces open-ended language with agreement percentages, which is stronger than a survey for understanding reasoning but weaker for precise population estimates.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

Remesh: Does Remesh recruit participants for me?

Yes, through On-Demand Recruit, typically delivering a panel within about 24 hours, or you can bring your own list.

Genedata vs Remesh

Genedata

Remesh

The short version

Where they differ

What each one covers

Only in Genedata

Only in Remesh

What people use each for

Genedata

Remesh

Where each one falls short

Genedata

Remesh

Pricing, plan by plan

Genedata

Remesh

Which should you pick?

Choose Genedata if

Choose Remesh if

Questions people ask

Answered from the vendors’ own pages

Related pages

More on Genedata

More on Remesh

Keep looking

Other head to heads